High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Xiao-Yan ShengHui-Jie AnYong-Yang HeYong-Feng YeJia-Lan ZhaoSai LiPublished in: Journal of clinical pharmacy and therapeutics (2022)
For patients carrying CYP2C19 LOF alleles after PCI, ticagrelor may be better than high-dose clopidogrel in reducing the risk of MACEs, while dyspnoea incidents should be alerted.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- high dose
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- end stage renal disease
- low dose
- stem cell transplantation
- atrial fibrillation
- newly diagnosed
- chronic kidney disease
- coronary artery bypass
- ejection fraction
- patient safety
- prognostic factors
- patient reported outcomes